Links

Homepage

Stock List

Search by Ticker

News

Login

Biogen Inc. (NASDAQ:BIIB)
Stock Analysis

BIIB305.71
▲ 10.1%28.05

Stock Analysis

The following stock analysis is based on 6.4 years of data (i.e. since Mar 17, 2014). All the stock history has been downloaded.

Stock Exchange

Biogen Inc. trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the sector.

Current Status of Biogen Inc.

It is currently trading at $305.71 ($277.66 the previous day).

Financials

The next reporting date is in 73 days (2020 10 21).

CNN estimates profits for the upcoming quarter will be $8.32 per share ($3.4B). The current Canada / US exchange rate is 1.3382.



Over the past 12 months, $0 worth of shares have been purchased and $1027003 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is -0.6% per year assuming steady exponential growth. The actual 5 year average is -4.44. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year281.99511698113-2.8+ Above Average
2 year290.01332-6.4- Below Average
3 year309.760798319339.1+ Above Average
4 year283.96538775511.8+ Above Average
5 year278.8128030303-23.9- Below Average
Biogen Inc. is projected by analysts to get to $305.00 within the next 12 months (-0.2%), but preticted targets range from as high as $386.00 (26.3%) and as low as $228(-25.4%).

Risk

The worst drop it has had in recent years is -54.5%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
10285.24RISING
30265.12RISING
60306.72DROPPING
150317.95DROPPING
365238.23RISING
800294.4DROPPING
1200286.89RISING
1600256.05RISING
2000391.66DROPPING


The P/E value is 8.98.

Tradingview BuySell Widget

Yahoo News Feed

FDA approves Rocheand's new spinal muscular atrophy drug

Sat, 08 Aug 2020 14:40:00 Roche Holding AG said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. Itand's the second drug to be approved by the regulator to treat the rare disease. ...... Read Full Article

Stock Market Today: Strong July Jobs Report Has a Dark Side

Fri, 07 Aug 2020 20:41:23 A better-than-expected employment report that saw 1.8 million U.S. jobs added in July didnand't give the markets much of a boost Friday.... Read Full Article

Trendingandnbsp; Market News Friday: Biogen, Mortgage Rates

Fri, 07 Aug 2020 20:34:00 U.S. household debt fell by its biggest margin in seven years in the second quarter. Biogen shares were rising Friday and mortgages rates dropped.... Read Full Article

Biogen Stock Surges As FDA Fast-Tracks Alzheimerand's Drug Application

Fri, 07 Aug 2020 20:14:44 Biogen stock powered up Friday after the firm said the U.S. Food and Drug Administration has decided to fast-track its application to bring a new Alzheimerand's disease drug to market.... Read Full Article

Biogen-Eisai Alzheimerand's Drug Gets FDA Priority Review

Fri, 07 Aug 2020 18:23:00 Biogen and Eisai said the FDA accepted for priority review their marketing application for aducanumab, an Alzheimerand's treatment.... Read Full Article

U.S. FDA approves Roche, PTC Therapeuticsand' spinal muscular atrophy drug

Fri, 07 Aug 2020 17:58:05 ... Read Full Article

Dow Jones Stays Red, Nasdaq Slumps As Trump Action Offsets Jobs Data

Fri, 07 Aug 2020 17:24:05 The Nasdaq turned sharply lower and the Dow Jones Industrial Average stayed red as President Trumpand's China order offset a better-than-expected jobs report.... Read Full Article

Dow Jones Today, Stocks Slump Despite July Payroll Surprise; China Stocks Dive On Trump Order; Biogen Gets FDA Nod

Fri, 07 Aug 2020 13:57:52 Stock futures were lower Friday, after July payrolls data, as China stocks dived and IBM fell furthest on the Dow Jones today.... Read Full Article

Biogen Stock Is Spiking Because Its Alzheimer’s Drug Takes Another Step Toward Approval

Fri, 07 Aug 2020 13:56:00 The Food and Drug Administration has granted priority review status to Biogen’s experimental Alzheimer’s disease drug aducanumab.... Read Full Article

Biogenand's stock rallies 11% after FDA accepts application for experimental Alzheimerand's drug

Fri, 07 Aug 2020 12:55:00 Shares of Biogen gained 11.7% in premarket trading on Friday after the company said the Food and Drug Administration (FDA) had accepted the application for the companyand's investigational, and somewhat controversial, Alzheimerand's disease treatment. The regulator is expected to make a ...... Read Full Article

Controversial Alzheimer’s Drug Takes Step Toward FDA Approval

Fri, 07 Aug 2020 12:38:01 (Bloomberg) -- Biogen Inc.’s experimental Alzheimer’s disease treatment aducanumab was granted priority review status by U.S. regulators, a move that could hasten the drug’s arrival on the market.The company said in a statement Friday that ...... Read Full Article

U.S. FDA accepts Biogenand's marketing application for Alzheimerand's drug

Fri, 07 Aug 2020 11:41:39 ... Read Full Article

FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimerand's Disease with Priority Review

Fri, 07 Aug 2020 11:30:00 * Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 * If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, Aug. 07, 2020 (...... Read Full Article

Biogen, Denali Announce Billion-Dollar Collaboration On Parkinsonand's Treatment

Thu, 06 Aug 2020 20:19:16 Biogen and Denali Therapeutics early Thursday announced a billion-dollar collaboration to move forward on testing on a Denali treatment for Parkinsonand's disease, sending DNLI stock soaring.... Read Full Article

Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss

Thu, 06 Aug 2020 13:21:01 Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.... Read Full Article

Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration

Thu, 06 Aug 2020 13:13:00 Shares of Denali Therapeutics Inc. rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc. announced a $465 million equity investment as part of a collaboration on Denaliand's treatment for Parkinsonand's disease. Biogenand's stock was little changed ahead of the ...... Read Full Article

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases

Thu, 06 Aug 2020 12:02:00 * Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders * Biogen to receive exclusive option rights to two programs for neurodegenerative diseases ...... Read Full Article

Kodak Has People Talking Again. Here’s What Its Stock Might Be Worth.

Wed, 05 Aug 2020 11:59:00 News about a generic-drug business sent shares of Kodak all over the place. Now investors have to figure out what a new pharma business is worth. It isn’t an easy job.... Read Full Article

Top Health Care Stocks for August 2020

Tue, 28 Jul 2020 19:18:23 Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as ...... Read Full Article

If You Invested $1,000 in Biogen During the Last Recession, This Is How Much You Would Have Today

Tue, 28 Jul 2020 15:11:00 You can also gather a much clearer picture of the strength of a stock based on how it does or doesn't perform during a global recession. If you own shares of Biogen (NASDAQ: BIIB) or are thinking about purchasing this ...... Read Full Article
<